

June 18, 2025

Notice Regarding Offer of Refunds to 340B Covered Entities

Kedrion Biopharma Inc. (“Kedrion”) has identified discrepancy in its calculation of the AMP and Best Price for several products which impacted 340B results beginning with Q4 2022 and ended Q1 2025:

NDC9	Product Description
00562-7805	RhoGAM Ultra Filtered Plus
76125-0150	KEDRAB 2ML 300iu
76125-0150	KEDRAB 10ML 1500iu
76125-0667	Koate Powder for Injection
70573-0099	Ryplazim 68.8 mg for Injection
76125-0792	Albuked 25% Solution for Injection
76125-0790	Albuked 5% Solution for Injection
00562-7806	MICRhoGAM Ultra Filtered Plus

Accordingly, Kedrion will proactively issue refunds via Apexus, LLC (“Apexus”), the 340B Prime Vendor, to 340B Covered Entities that purchased these products during the quarters identified above and are owed a refund of more than \$10 dollars in the aggregate for the impacted quarters. Apexus will work with Kedrion to validate wholesaler pharmacy account information for each covered entity. Once validated, Apexus will work with the wholesalers to facilitate the processing of credit for the differences between the amounts that the covered entity was charged and the 340B ceiling price during the specified periods. If an active wholesaler account cannot be identified within two weeks after the initial communication, then Apexus will work to issue an ACH or check to those entities.

Covered entities that believe they are owed a refund of less than \$10 dollars in the aggregate may request a refund by contacting Kedrion at 340BProgram@kedrion.com for assistance. Please include “340B Reimbursement” and your entities 340B ID in the subject line.

To enable processing of such refund requests, Covered Entities (CE’s) must provide the following information:

Covered Entity ID, NDC Number, Quantity, Original Purchase Invoice Number, Invoice Date, and the Wholesaler the product was purchased through for all affected products.

If a 340B Covered Entity believes it is due a refund of more than \$10 dollars in the aggregate and is not contacted by Apexus, the Covered Entity may reach out to Kedrion at 340BProgram@kedrion.com for assistance. Please include “340B Reimbursement” and your entities 340B ID in the subject line.

Kedron has asked the Health Resources and Services Administration (“HRSA”) to post this Notice on the HRSA’s public website to ensure transparency to all 340B Covered Entities regarding the 340B Ceiling Price recalculations for the products identified above and Kedron’s refund process. Please direct any questions and/or requests for additional information to Kedron at 340BProgram@kedron.com.